Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
QuintilesIMS
US Department of Justice
Merck
Express Scripts
McKinsey
US Army
Teva
Cerilliant

Generated: June 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,822,438

« Back to Dashboard

Which drugs does patent 8,822,438 protect, and when does it expire?

Patent 8,822,438 protects ZYTIGA and is included in one NDA.

This patent has twenty-six patent family members in eighteen countries.
Summary for Patent: 8,822,438
Title:Methods and compositions for treating cancer
Abstract: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17.alpha.-hydroxylase/C.sub.17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3.beta.-acetoxy-17-(3-pyridyl)androsta-5,16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17.alpha.-hydroxylase/C.sub.17,20-lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.
Inventor(s): Auerbach; Alan H. (Hermosa Beach, CA), Belldegrum; Arie S. (Los Angeles, CA)
Assignee: Janssen Oncology, Inc. (Los Angeles, CA)
Application Number:13/034,340
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,822,438
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,822,438

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Biotech ZYTIGA abiraterone acetate TABLET;ORAL 202379-001 Apr 28, 2011 RX Yes No ➤ Sign Up ➤ Sign Up USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ➤ Sign Up
Janssen Biotech ZYTIGA abiraterone acetate TABLET;ORAL 202379-001 Apr 28, 2011 RX Yes No ➤ Sign Up ➤ Sign Up USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY ➤ Sign Up
Janssen Biotech ZYTIGA abiraterone acetate TABLET;ORAL 202379-001 Apr 28, 2011 RX Yes No ➤ Sign Up ➤ Sign Up USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER ➤ Sign Up
Janssen Biotech ZYTIGA abiraterone acetate TABLET;ORAL 202379-002 Apr 14, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Covington
US Department of Justice
Accenture
Merck
Queensland Health
Moodys
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.